How Will US Tariffs On Branded Pharma Impact Sun Pharma, Wockhardt And Biocon?
INCRED Asset Management has flagged possible turbulence for leading Indian pharmaceutical companies after the US announced tariffs on branded pharmaceutical products. While details of the final implementation are awaited, early signals point towards potential disruptions in specialty revenues for Sun Pharma, Wockhardt, and even Biocon, if biosimilars are included in the “branded” category. The uncertainty has left investors cautious, with many preferring to stay on the sidelines until greater clarity emerges.
About Sun Pharma And Its US Dependence
Sun Pharmaceutical Industries is India’s largest drugmaker and a global leader in specialty products, generics, and complex formulations. In FY25, about 20% of its total revenues came from specialty drugs, with 70–80% of that generated from the US market. This heavy dependence on the US makes Sun Pharma particularly vulnerable to changes in tariff regimes. Specialty medicines, unlike plain generics, often command higher margins, which means any disruption here can significantly affect profitability and long-term growth.
Wockhardt And Biocon: Different Business Models, Similar Risks
Wockhardt, though smaller in scale than Sun Pharma, has also built a significant part of its portfolio around branded products, particularly in critical care and anti-infectives. If tariffs cover a wide range of branded formulations, its already stressed balance sheet could face further pressure. Biocon, on the other hand, is heavily invested in biosimilars. While these are technically “similar” to biologics and often treated as generics, there is speculation that some may be classified under “branded” by US regulators. If that happens, Biocon could see unexpected tariff-related headwinds at a time when it is expanding its global biosimilar footprint.
How The Tariffs Could Reshape The Pharma Trade
The US remains the largest market for Indian pharma exports, with branded and specialty drugs forming a significant portion of value-added products. A tariff regime on these could have a twofold effect: raising costs for Indian manufacturers while potentially benefiting domestic US pharma companies. For Indian firms, margins may come under pressure unless they can negotiate price adjustments or shift focus to non-tariffed categories. Investors need to carefully evaluate which companies have diversified revenue bases and which are overly reliant on US branded sales.
For those tracking derivatives and index strategies during this volatile phase, here’s a quick route 👉 Nifty Tip | BankNifty Tip.
Why INCRED Asset Management Prefers To Stay Away
INCRED Asset Management has openly stated that it would not touch pharma investments until more clarity emerges on the tariff structure. The reason is straightforward—branded drugs and biosimilars carry significant profit contribution for Sun Pharma, Wockhardt, and Biocon. With uncertainty around definitions and scope, predicting earnings becomes speculative at best. Asset managers are preferring to wait until either exemptions are clarified or companies provide updated guidance on how they will mitigate the impact.
Investor Takeaway
The US tariffs on branded pharmaceutical products introduce fresh uncertainty for Indian majors. Sun Pharma’s specialty dependence, Wockhardt’s financial stress, and Biocon’s biosimilar exposure make them sensitive to these developments. Until clarity emerges, investors may prefer a wait-and-watch stance, focusing instead on sectors with clearer growth visibility. Those seeking consistent guidance on navigating these policy shifts can always explore deeper market coverage at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
